Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC Read more about Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC
Agios Outlines Key Clinical Development & Research Strategies Read more about Agios Outlines Key Clinical Development & Research Strategies
Agios to Webcast R&D Day on October 16, 2015 Read more about Agios to Webcast R&D Day on October 16, 2015
Agios to Present at Leerink Partners Rare Disease Roundtable Read more about Agios to Present at Leerink Partners Rare Disease Roundtable
Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress Read more about Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress
Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015 Read more about Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015
Agios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015 Read more about Agios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015
Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation Read more about Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation
Agios Appoints Maykin Ho, Ph.D., to its Board of Directors Read more about Agios Appoints Maykin Ho, Ph.D., to its Board of Directors
Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency Read more about Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency